Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Operating Expenses
Antengene Corporation Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Operating Expenses
-¥723.1m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Expenses
-¥6.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Expenses
-¥1.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-16%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Expenses
-¥16.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-15%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Expenses
-¥6.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-14%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Operating Expenses
-¥685.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Operating Expenses?
Operating Expenses
-723.1m
CNY
Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Operating Expenses amounts to -723.1m CNY.
What is Antengene Corporation Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-39%
Over the last year, the Operating Expenses growth was 29%. The average annual Operating Expenses growth rates for Antengene Corporation Ltd have been 37% over the past three years , -39% over the past five years .
You don't have any saved screeners yet